Keywords: ماریوکر; Natalizumab; Progressive multifocal leukoencephalopathy; Immune reconstitution inflammatory syndrome; Maraviroc;
مقالات ISI ماریوکر (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ماریوکر; Maraviroc; Chemokine receptor type 5 (CCR5) inhibition; CCR5 blockade; Lymphocyte chemotaxis;
Keywords: ماریوکر; Maraviroc; CCR5 antagonists; Antiretroviral treatment; Salvage treatment; Immune discordance; CCR5 tropism;
Keywords: ماریوکر; HIV-1; human immunodeficiency virus type 1; MVC; maraviroc; GTD; genotypic tropism determination; FPR; false-positive rate; V3; third hypervariable loop; EP; electropherogram dataset; ME; manually-edited sequence; AS; automatic sequence; SEP; single-elect
Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro
Keywords: ماریوکر; Esophageal squamous cell carcinoma; CCL5; Maraviroc; Tumor progression;
Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis
Keywords: ماریوکر; GVHD; Chemokine receptor blockade; Maraviroc;
Next generation sequencing reveals a high frequency of CXCR4 utilizing viruses in HIV-1 chronically infected drug experienced individuals in South Africa
Keywords: ماریوکر; Next generation sequencing; Chronic HIV infection; Co-receptor usage; Maraviroc; South Africa;
CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward
Keywords: ماریوکر; Conditioned place preference; C-C motif chemokines; Cytokines; HIV-associated neurocognitive disorders; Maraviroc; NeuroAIDS; Opiate dependence; Opiate tolerance; Precipitated withdrawal; Warm-water tail-withdrawal test;
Results of the first international HIV-1 coreceptor proficiency panel test
Keywords: ماریوکر; HIV; Tropism; Coreceptor; Geno2pheno; Maraviroc; MVC;
HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites
Keywords: ماریوکر; HIV; AIDS; CD4; gp120; CCR5; PNGS; Subtype B; CRF01_AE; Maraviroc; Envelope;
Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up
Keywords: ماریوکر; HIV; Primary HIV infection; Maraviroc; CD4;
Evaluating the appropriateness of dosing adjustments in the coadministration of maraviroc and CYP3A inhibitors: A literature review
Keywords: ماریوکر; Maraviroc; CCR5 antagonism; Extended interval;
Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients
Keywords: ماریوکر; Human immunodeficiency virus; HIV Infection; CCR5 antagonist; Maraviroc; Tropism
Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maraviroc
Keywords: ماریوکر; EC, Ethyl cellulose; PVP, polyvinylpyrrolidone; Qs, shell flow rate; Qc, core flow rateCoaxial; Core-shell; Drug delivery; Electrospinning; Maraviroc; Microbicide
Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application
Keywords: ماریوکر; Nanoparticles; Liposomes; Chemoprophylaxis; Maraviroc; TDF
HIV-1 adaptation to low levels of CCR5 results in V3 and V2 loop changes that increase envelope pathogenicity, CCR5 affinity and decrease susceptibility to Maraviroc
Keywords: ماریوکر; CCR5; chemokine receptor; Env; Envelope; MVC; Maraviroc; DMEM; Dulbecco׳s Modified Eagles medium; RT; Reverse Transcriptase; HIV; Human Immunodeficiency Virus; AIDS; Acquired Immune Deficiency Syndrome; FPR; False Positive Ratio; HIV; AIDS; Co-receptor;
Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naive HIV-infected subjects
Keywords: ماریوکر; Regulatory T-cells; HIV; maraviroc; CCR5; naive-Treg; effector-Treg; non-Treg; homeostasis;
Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029
Keywords: ماریوکر; Dual/mixed virus; HIV; maraviroc; phenotypic activity; UDPS;
Engineering and exploitation of a fluorescent HIV-1 gp120 for live cell CD4 binding assays
Keywords: ماریوکر; ART; anti-retroviral therapy; BNAbs; broadly neutralizing antibodies; CS; cellulose sulfate; ER; endoplasmic reticulum; FP; fluorescent protein; FRAP; fluorescence recovery after photobleaching; gp120; HIV-1 envelope glycoprotein; MR; maraviroc; PHA; phyt
Macrophage-sensory neuronal interaction in HIV-1 gp120-induced neurotoxicity
Keywords: ماریوکر; cytokines; HIV envelope protein; macrophages; maraviroc; peripheral nervous system diseases; peripheral neuropathies;
Polyanionic carbosilane dendrimer-conjugated antiviral drugs as efficient microbicides: Recent trends and developments in HIV treatment/therapy
Keywords: ماریوکر; HIV-1/HSV-2; Maraviroc; Microbicide; Polyanionic carbosilane dendrimers; Tenofovir;
Maraviroc 150Â mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study
Keywords: ماریوکر; Antiretroviral therapy; human immunodeficiency virus; maraviroc; naive patients; nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen;
Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure
Keywords: ماریوکر; HIV; Tropism; CCR5; Maraviroc; AIDS; Coreceptors
A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma
Keywords: ماریوکر; Maraviroc; HPLC-MS; HIV; Therapeutic drug monitoring; Plasma
Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy
Keywords: ماریوکر; HIV infection; cART; Maraviroc; NRTIs; Inflammatory markers;
Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma
Keywords: ماریوکر; Maraviroc; HIV; CCR5 antagonist; Assay validation; LC-MS/MS
Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression
Keywords: ماریوکر; CCTG, The California Collaborative Treatment Group; UCSD, University of California San Diego; UCLA, University of California Los Angeles; USC, University of Southern CaliforniaHIV; CCR5 inhibitors; Maraviroc; Gene expression; CD4+ T cell recovery
Performance of a clonal-based HIV-1 tropism phenotypic assay
Keywords: ماریوکر; MVC; maraviroc; R5 viruses; viruses that use CCR5 co-receptor; HIV-1; human immunodeficiency virus 1; X4 viruses; viruses that use co-receptor CXCR4; X4R5/Dual-tropic; viruses that use both co-receptors CCR5 and CXCR4 co-receptors; D/M; mixed virus popula
Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic–tandem mass spectrometric (LC–MS/MS) analysis
Keywords: ماریوکر; Dapivirine; Maraviroc; Cervicovaginal fluid; Validation; Antiretroviral
Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc
Keywords: ماریوکر; HIV-1; CCR5; CCR5 antagonist; Maraviroc; Fusion protein
The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer
Keywords: ماریوکر; Cancer; CCR5-CCL5; CXCR4-CXCL12; Maraviroc; Plerixafor; Personalized therapy;
Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078
Keywords: ماریوکر; ALT; alanine aminotransferase; AST; aspartate aminotransferase; ES; enhanced sensitivity; FPR; false-positive rate; g2p; geno2pheno; MVC; maraviroc; NR; non-reportable; QD; once daily; sff; Standard Flowgram Format; CXCR5; Genotype; HIV-1; Maraviroc; Phen
Analysis of primary resistance mutations to HIV-1 entry inhibitors in therapy naive subtype C HIV-1 infected mother-infant pairs from Zambia
Keywords: ماریوکر; HIV-1; human immunodeficiency virus type 1; MTCT; mother-to-child transmission; MIP; mother-infant pair; NNRTI; non-nucleoside reverse transcriptase inhibitor; DRAM; drug resistance-associated mutation; IFA; immunofluorescence assay; PBMC; peripheral bl
Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation
Keywords: ماریوکر; Maraviroc; Cytokines; Lipodystrophy; Adipocytes; Inflammation;
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection
Keywords: ماریوکر; HIV; Tropism; Genotyping test; Trofileâ¢; Maraviroc;
The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets
Keywords: ماریوکر; HIV-1; Maraviroc; Resistance; T-cell; Macrophage; Tropism; Env; gp120
A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action
Keywords: ماریوکر; Controlled release; HIV microbicide; Dapivirine; Maraviroc; Vaginal ring
Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC
Keywords: ماریوکر; ARV; antiretroviral; FDA; Food and Drug Administration; ENF; Enfuvirtide; MVC; Maraviroc; VCV; Vicriviroc; HR1; first heptad repeat region; HR2; second heptad repeat region; pol; polimerase; env; envelope; CRF; circulating recombinant form; URF; unique re
Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment
Keywords: ماریوکر; MVC, maraviroc; MCT, maraviroc clinical test; cART, CXCR4 (X4), combined antirretroviral therapy; D/M, dual/mixedAntiretroviral therapy; Maraviroc; HIV tropism; CCR5
T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity
Keywords: ماریوکر; HIV; Maraviroc; CCR5 antagonist; CD4-positive T-lymphocytes; Viral tropism
Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice
Keywords: ماریوکر; CCR5; CXCR4; genotypic; HIV-1; maraviroc; R5-tropic; tropism; X4-tropic;
V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc
Keywords: ماریوکر; CCR5; Small molecule CCR5 inhibitors; V3 sequence; Drug resistance; CCR5 NT; Maraviroc; Vicriviroc
Access to C-protected β-amino-aldehydes via transacetalization of 6-alcoxy tetrahydrooxazinones and use for pseudo-peptide synthesis
Keywords: ماریوکر; Transacetalization; Peptide aldehyde; β-Amino acetal; Maraviroc; Peptide coupling;
Discordance rates between Trofile® test and short-term virological response to maraviroc
Keywords: ماریوکر; ES-Trofile®, enhanced sensitivity Trofile®; X4, CXCR4; MRV, maraviroc; MCT, Maraviroc Clinical Test; R5, CCR5; cART, combined antiretroviral therapy; D/M, dual/mixedTropism assay; Maraviroc; Clinical approach
Rescue of HIV-1 long-time archived X4 strains to escape maraviroc
Keywords: ماریوکر; HIV-1 tropism; Recombination; Maraviroc; Evolution; Interleukin-2;
Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C
Keywords: ماریوکر; Griffithsin; Tenofovir; Maraviroc; Enfuvirtide; Synergy; Combination index; Microbicide; HIV-1 clade C; Glycosylation; PBMCs
Analysis of co‐receptor usage of circulating viral and proviral HIV genome quasispecies by ultra‐deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment
Keywords: ماریوکر; CCR5; co‐receptor; CXCR4; HIV; Maraviroc; NGS; pyrosequencing; tropism; UDPS
A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc
Keywords: ماریوکر; HIV-1; CCR5; gp120; V3 loop; Viral entry; Maraviroc; Noncompetitive resistance
Indicación de uso de los antirretrovirales de última generación en la práctica clÃnica actual
Keywords: ماریوکر; Darunavir; Maraviroc; Etravirina; Raltegravir; Resistencia multiple a medicamentos; Tratamiento antirretroviral; Infección por VIH; Darunavir; Maraviroc; Etravirine; Raltegravir; Multiple drug resistance; Antiretroviral treatment; HIV infection;
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro
Keywords: ماریوکر; HIV-1 tropism; Maraviroc; Pyrosequencing; Phenotyping; Env mutations